Literature DB >> 3290901

Active human immunodeficiency virus protease is required for viral infectivity.

N E Kohl1, E A Emini, W A Schleif, L J Davis, J C Heimbach, R A Dixon, E M Scolnick, I S Sigal.   

Abstract

Retroviral proteins are synthesized as polyprotein precursors that undergo proteolytic cleavages to yield the mature viral proteins. The role of the human immunodeficiency virus (HIV) protease in the viral replication cycle was examined by use of a site-directed mutation in the protease gene. The HIV protease gene product was expressed in Escherichia coli and observed to cleave HIV gag p55 to gag p24 and gag p17 in vitro. Substitution of aspartic acid residue 25 (Asp-25) of this protein with an asparagine residue did not affect the expression of the protein, but it eliminated detectable in vitro proteolytic activity against HIV gag p55. A mutant HIV provirus was constructed that contained the Asn-25 mutation within the protease gene. SW480 human colon carcinoma cells transfected with the Asn-25 mutant proviral DNA produced virions that contained gag p55 but not gag p24, whereas virions from cells transfected with the wild-type DNA contained both gag p55 and gag p24. The mutant virions were not able to infect MT-4 lymphoid cells. In contrast, these cells were highly sensitive to infection by the wild-type virions. These results demonstrate that the HIV protease is an essential viral enzyme and, consequently, an attractive target for anti-HIV drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290901      PMCID: PMC280500          DOI: 10.1073/pnas.85.13.4686

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  In vitro cleavage of avian retrovirus gag proteins by viral protease p15.

Authors:  V M Vogt; A Wight; R Eisenman
Journal:  Virology       Date:  1979-10-15       Impact factor: 3.616

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

5.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

6.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

7.  Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity.

Authors:  I Katoh; Y Yoshinaka; A Rein; M Shibuya; T Odaka; S Oroszlan
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

8.  Translational readthrough of an amber termination codon during synthesis of feline leukemia virus protease.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

10.  Amino acid sequence of p15 from avian myeloblastosis virus complex.

Authors:  R T Sauer; D W Allen; H D Niall
Journal:  Biochemistry       Date:  1981-06-23       Impact factor: 3.162

View more
  346 in total

1.  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Authors:  D Xie; S Gulnik; E Gustchina; B Yu; W Shao; W Qoronfleh; A Nathan; J W Erickson
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.

Authors:  A Caflisch; H J Schramm; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

3.  Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Authors:  J Lescar; J Brynda; P Rezacova; R Stouracova; M M Riottot; V Chitarra; M Fabry; M Horejsi; J Sedlacek; G A Bentley
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

4.  Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

Authors:  J Trylska; J Antosiewicz; M Geller; C N Hodge; R M Klabe; M S Head; M K Gilson
Journal:  Protein Sci       Date:  1999-01       Impact factor: 6.725

5.  Genetic selection for dissociative inhibitors of designated protein-protein interactions.

Authors:  S H Park; R T Raines
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

6.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Local and spatial factors determining HIV-1 protease substrate recognition.

Authors:  S Hazebrouck; V Machtelinckx-Delmas; J J Kupiec; P Sonigo
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

8.  Segmental analysis of molecular surface electrostatic potentials: application to enzyme inhibition.

Authors:  Tore Brinck; Ping Jin; Yuguang Ma; Jane S Murray; Peter Politzer
Journal:  J Mol Model       Date:  2003-02-21       Impact factor: 1.810

Review 9.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.